MA49751B1 - Agents antifongiques à activité améliorée en ph acide - Google Patents
Agents antifongiques à activité améliorée en ph acideInfo
- Publication number
- MA49751B1 MA49751B1 MA49751A MA49751A MA49751B1 MA 49751 B1 MA49751 B1 MA 49751B1 MA 49751 A MA49751 A MA 49751A MA 49751 A MA49751 A MA 49751A MA 49751 B1 MA49751 B1 MA 49751B1
- Authority
- MA
- Morocco
- Prior art keywords
- infections
- enfumafungin
- useful
- acidic
- under acidic
- Prior art date
Links
- 230000002378 acidificating effect Effects 0.000 title abstract 3
- 229940121375 antifungal agent Drugs 0.000 title abstract 2
- 239000003429 antifungal agent Substances 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- IAOFPTKYKOAKGZ-CRWQHXLTSA-N enfumafungin Chemical compound O([C@H]1[C@H](OC(C)=O)C[C@@]23C(O)OC[C@]1(C)[C@@H]2CC[C@@H]1[C@@]2(C)CC[C@]([C@H]([C@]2(C)CC=C13)C(O)=O)(C)[C@H](C)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IAOFPTKYKOAKGZ-CRWQHXLTSA-N 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 abstract 1
- 206010014568 Empyema Diseases 0.000 abstract 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 206010000269 abscess Diseases 0.000 abstract 1
- 210000003484 anatomy Anatomy 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 108010001062 polysaccharide-K Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 150000003648 triterpenes Chemical class 0.000 abstract 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Les composés antifongiques triterpénoïdes dérivés de l'enfumafungine sont utilisés pour traiter ou prévenir les infections fongiques se produisant en ou sous conditions acides, où le ph est inférieur à environ 7, du fait que leur efficacité est, de façon inattendue, améliorée sous de telles conditions. Les triterpénoïdes dérivés de l'enfumafungine (ou des sels ou hydrates de qualité pharmaceutique de ces derniers) sont des inhibiteurs de la synthèse des (1,3)-ß-d-glucanes et sont utilisables dans le traitement ou la prévention d'infections à levures ou à champignons filamenteux qui se développent dans les zones anatomiques à ph bas, telles que la cavité vaginale, ou sous des conditions d'environnement local acides telles que celles observées dans des abcès fongiques, dans l'empyème, ou dans les infections du tractus gastro-intestinal supérieur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541370P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/044619 WO2019028034A1 (fr) | 2017-08-04 | 2018-07-31 | Agents antifongiques à activité améliorée en ph acide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49751A MA49751A (fr) | 2020-06-10 |
| MA49751B1 true MA49751B1 (fr) | 2022-12-30 |
Family
ID=63209698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49751A MA49751B1 (fr) | 2017-08-04 | 2018-07-31 | Agents antifongiques à activité améliorée en ph acide |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11534433B2 (fr) |
| EP (3) | EP4732902A2 (fr) |
| JP (1) | JP7214714B2 (fr) |
| KR (1) | KR102807716B1 (fr) |
| CN (2) | CN111093655A (fr) |
| AU (2) | AU2018309718B2 (fr) |
| BR (1) | BR112020002290A2 (fr) |
| CA (1) | CA3071940A1 (fr) |
| CY (1) | CY1125690T1 (fr) |
| DK (1) | DK3661503T3 (fr) |
| EA (1) | EA202090445A1 (fr) |
| ES (1) | ES2932658T3 (fr) |
| FI (1) | FI3661503T3 (fr) |
| HR (1) | HRP20221414T1 (fr) |
| HU (1) | HUE060508T2 (fr) |
| LT (1) | LT3661503T (fr) |
| MA (1) | MA49751B1 (fr) |
| MD (1) | MD3661503T2 (fr) |
| MX (1) | MX2020001399A (fr) |
| PL (1) | PL3661503T3 (fr) |
| PT (1) | PT3661503T (fr) |
| RS (1) | RS63746B1 (fr) |
| SI (1) | SI3661503T1 (fr) |
| SM (1) | SMT202200461T1 (fr) |
| TW (1) | TWI805600B (fr) |
| WO (1) | WO2019028034A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021016876A2 (pt) * | 2019-02-27 | 2021-11-03 | Scynexis Inc | Métodos para tratar e para prevenir pneumonia por pneumocystis, métodos para tratar e para prevenir pneumonia por pneumocystis jirovecii, preparação de um medicamento para tratar ou prevenir pneumonia por pneumocystis jirovecii, e, uso de um composto |
| AU2020276595B2 (en) * | 2019-05-16 | 2025-12-04 | Scynexis, Inc. | Antifungal Agents for Candida Auris Decolonization |
| WO2022140646A1 (fr) * | 2020-12-26 | 2022-06-30 | Mycovia Pharmaceuticals, Inc | Schéma posologique de l'otéséconazole |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5756472A (en) | 1996-01-31 | 1998-05-26 | Merck & Co., Inc. | Antifungal agent obtained from hormonema |
| JP5245057B2 (ja) | 2006-04-03 | 2013-07-24 | メルク・シャープ・アンド・ドーム・コーポレーション | 抗真菌剤 |
| WO2010019204A1 (fr) | 2008-08-12 | 2010-02-18 | Merck Sharp & Dohme Corp. | Agents antifongiques |
| KR101686075B1 (ko) * | 2008-08-12 | 2016-12-13 | 싸이넥시스, 인크. | 항균제 |
| HRP20220544T1 (hr) | 2015-01-19 | 2022-08-05 | Scynexis, Inc. | Nove soli i polimorfi scy-078 |
| MA49889A (fr) * | 2017-04-10 | 2020-06-24 | Scynexis Inc | Agents antifongiques utilisés en association |
-
2018
- 2018-07-31 KR KR1020207005972A patent/KR102807716B1/ko active Active
- 2018-07-31 BR BR112020002290-0A patent/BR112020002290A2/pt not_active Application Discontinuation
- 2018-07-31 US US16/636,230 patent/US11534433B2/en active Active
- 2018-07-31 CA CA3071940A patent/CA3071940A1/fr active Pending
- 2018-07-31 SI SI201830810T patent/SI3661503T1/sl unknown
- 2018-07-31 LT LTEPPCT/US2018/044619T patent/LT3661503T/lt unknown
- 2018-07-31 ES ES18755632T patent/ES2932658T3/es active Active
- 2018-07-31 SM SM20220461T patent/SMT202200461T1/it unknown
- 2018-07-31 EA EA202090445A patent/EA202090445A1/ru unknown
- 2018-07-31 RS RS20221058A patent/RS63746B1/sr unknown
- 2018-07-31 HR HRP20221414TT patent/HRP20221414T1/hr unknown
- 2018-07-31 AU AU2018309718A patent/AU2018309718B2/en active Active
- 2018-07-31 DK DK18755632.9T patent/DK3661503T3/da active
- 2018-07-31 PL PL18755632.9T patent/PL3661503T3/pl unknown
- 2018-07-31 JP JP2020505869A patent/JP7214714B2/ja active Active
- 2018-07-31 EP EP25222120.5A patent/EP4732902A2/fr active Pending
- 2018-07-31 PT PT187556329T patent/PT3661503T/pt unknown
- 2018-07-31 MD MDE20200607T patent/MD3661503T2/ro not_active IP Right Cessation
- 2018-07-31 WO PCT/US2018/044619 patent/WO2019028034A1/fr not_active Ceased
- 2018-07-31 EP EP18755632.9A patent/EP3661503B1/fr not_active Revoked
- 2018-07-31 MA MA49751A patent/MA49751B1/fr unknown
- 2018-07-31 CN CN201880059398.2A patent/CN111093655A/zh active Pending
- 2018-07-31 MX MX2020001399A patent/MX2020001399A/es unknown
- 2018-07-31 CN CN202410653474.XA patent/CN118542868A/zh active Pending
- 2018-07-31 FI FIEP18755632.9T patent/FI3661503T3/fi active
- 2018-07-31 EP EP22193944.0A patent/EP4169514B1/fr active Active
- 2018-07-31 HU HUE18755632A patent/HUE060508T2/hu unknown
- 2018-08-03 TW TW107127013A patent/TWI805600B/zh active
-
2022
- 2022-11-18 US US17/990,656 patent/US20230364067A1/en not_active Abandoned
- 2022-12-06 CY CY20221100767T patent/CY1125690T1/el unknown
-
2024
- 2024-10-21 AU AU2024227501A patent/AU2024227501A1/en active Pending
- 2024-12-03 US US18/967,641 patent/US20260000656A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4277616A4 (fr) | Formulations d'agents pénétrants transdermiques pour l'administration de médicaments | |
| MA49751B1 (fr) | Agents antifongiques à activité améliorée en ph acide | |
| MA52219B1 (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| EP3765611A4 (fr) | Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés | |
| MA49673B1 (fr) | Combinaison comprenant du palbociclib et 6-(2,4-dichlorophényl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulène-2-acide carboxylique et sa utilisation pour le traitement du cancer | |
| MA39726A (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
| MX390145B (es) | Formulaciones para la administracion de eflornitina | |
| EP4306127A4 (fr) | Composition pharmaceutique pour le traitement ou la prévention de la myasthénie grave | |
| EP3760626A4 (fr) | Nouveau composé et composition pour la prévention, l'amélioration ou le traitement de la fibrose ou de la stéatohépatite non alcoolique le comprenant en tant que principe actif | |
| EP3804736A4 (fr) | Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire | |
| EA202091725A1 (ru) | Офтальмические композиции, содержащие биластин, бета-циклодекстрин и по крайней мере одно желатинирующее вещество | |
| CO5050328A1 (es) | Sistema solvente para la mejor penetracion de compuestos farmaceuticos | |
| MA43876A (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| EP4209227A4 (fr) | Composition pharmaceutique pour la prévention et/ou le traitement du prurit en dialyse contenant comme principe actif un antagoniste de l'il-31 | |
| EP4209216A4 (fr) | Composition pharmaceutique pour le traitement de tumeurs | |
| WO2019032528A8 (fr) | Inhibiteurs bicycliques d'histone désacétylase | |
| EP4159235A4 (fr) | Composition pharmaceutique contenant un agoniste de pd-1 pour traiter ou prévenir une maladie médiée par th2 | |
| BR0010084A (pt) | Composição farmacêutica, processos para prevenir, tratar ou inibir o desenvolvimento de retinopatia simples ou retinopatia proliferativa, e para aumentar potencial retiniano ou edema retiniano de mamìfero, e, uso de um composto | |
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida | |
| EP3650029A4 (fr) | Composition pharmaceutique pour la prévention et le traitement de la néphropathie diabétique, contenant un dérivé d'adénosine | |
| FR3100128B1 (fr) | Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications | |
| EP3904518A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant un modulateur d'expression tut4/7 | |
| EA201992817A1 (ru) | Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении | |
| EA202192257A1 (ru) | Комбинация кремния и магния для предупреждения и лечения мышечных судорог | |
| MX389613B (es) | Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. |